/r/shroomstocks
A community of stock market investors in the legal psychedelics sector. Global drug policy is changing, and psychedelic therapies are next in line for decriminalization, research, and sale. Please subscribe and contribute anything that relates to the legal industry of psychedelics.
You can also visit our Discord server: https://discord.gg/Pq8VDfs.
Welcome to Shroom Stocks!
A community that encourages good investing practices, this sub-reddit intends to educate and prepare investors for the Mush RushTM. Global drug policy is changing, and psilocybin mushrooms are likely next in line for decriminalization, research, and sale. Please subscribe and contribute anything that relates to psilocybin investing.
Community Rules/Policies
Breaking any of the following rules is grounds for having your post/comment removed
Be respectful and kind
Titles must be descriptive, no click-bait titles, use article's actual title in post's wherever possible.
Posts must have a clear connection to the psilocybin mushroom industry
NEWS Flair = Content with big breaking news, i.e. legalization in a state, country, province / companies merging, buyouts, getting licenses
PRESS RELEASE = Anything from a company or articles that start with "X company is pleased to announce"
REPORT = Short pieces of news that's not that exciting, not a press release, but still objective, i.e. congress debates psilocybin legalization, X province to make announcement on legalization, results of a poll.
EDITORIAL = Anything that doesn't fit into above OR is clearly an opinion piece speculating the psilocybin market, legalization, effects, benefits, companies. Also, super lengthy in depth reports.
Our Discord
/r/shroomstocks
63,265 Subscribers
Will RFK reschedule psychedelics to a schedule 2 or 3 drug?
Will RFK reschedule psychedelics to a schedule 2 or 3 drug?
16:49 UTC
21:33 UTC
Anyone have deep DD on PBM?
I’m holding a position and taking interest in the investment category overall. I have a few positions, but see PBM (in particular) as being undervalued. In my view, palliative care pursued by PBM is also lower clinical approval risk than some other indications- and therefore could warrant a higher valuation in short term. If anyone is willing to provide supportive or contrary data, it’d be much appreciated. Happy to be a new member of this sub!
19:40 UTC
Tryp Therapeutics successfully completes Phase 1b study with TRP-8803 for Binge Eating Disorder.
05:32 UTC
Small Cap Sues 2 Mega Banks For $700,000,000 For Manipulating Its Stock
19:23 UTC
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies
https://www.nature.com/articles/s41380-024-02800-5
Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. However, there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders.
Methods We conducted a systematic review, meta-analysis, and overview of reviews to assess the incidence of psychedelic-induced psychosis and symptom exacerbation in schizophrenia. Our pre-registered protocol (CRD42023399591) covered: LSD, psilocybin, mescaline, DMT, and MDMA, using data from Embase, PubMed, PsyARTICLES, PsyINFO, and trial registries up to November 2023. A random-effects model was used to calculate psychosis incidence, with standardized assessments of study quality.
Results From 131 publications, we analyzed 14 systematic reviews, 20 reviews, 35 randomized-controlled trials (RCTs), 10 case-control studies, 30 uncontrolled trials (UCTs), and 22 cohort studies, most of which were low quality. Meta-analysis of nine studies showed an incidence of psychedelic-induced psychosis at 0.002% in population studies, 0.2% in UCTs, and 0.6% in RCTs. In UCTs including individuals with schizophrenia, 3.8% developed long-lasting psychotic symptoms. Of those with psychedelic-induced psychosis, 13.1% later developed schizophrenia. Sensitivity analyses confirmed the results.
Conclusion In summary, the reviewed evidence suggests that schizophrenia might not be a definite exclusion criterion for clinical trials exploring safety and efficacy of psychedelics for treatment-resistant depression and negative symptoms. However, given the low quality and limited number of studies, more high-quality research is needed, and a conservative approach is recommended until further data is available.
10:56 UTC
Mehmet Oz - Nominee to run CMS
"All these drugs are helping people with PTSD, hard depression, alcoholism, cigarette addiction. It's shockingly exciting. What a good way to deal with depression"
CMS is the federal agency that provides health coverage to more than 160 million through Medicare, Medicaid, the Children's Health Insurance Program, and the Health Insurance Marketplace. CMS works in partnership with the entire health care community to improve quality, equity and outcomes in the health care system.
10:51 UTC
Cybin unveils unprecedented 12 month results
08:12 UTC
First Week
My watchlist today; what are your favorite penny stocks in this sector?
00:35 UTC
13:58 UTC
Cybin - now: "cash to go to topline data" & "we will likely need to raise more"
11:27 UTC
Cybin - 8 months ago: "This raise is entirely designed to fund the Phase 3 program"
11:25 UTC
November 25, 2024 | r/shroomstocks weekly discussion thread
This thread is for questions and general discussion relating to the psychedelics industry. The weekly thread will refresh every Monday morning before stock market open.
11:02 UTC
07:11 UTC
05:31 UTC
My Take: Why LSD is the winner in the Pharmaceutical Space.
03:56 UTC
The Makary tie to psychedelics is just flat out wrong. Hate when “terrible DD” happens …..
Let’s not spread hopium that’s not there…. Please and thank you
21:37 UTC